Olga Lomovskaya is senior vice president of discovery and clinical microbiology. Olga has more than 25 years of experience in anti-infective R&D and is a world-recognized expert in the field of antimicrobial resistance.
Prior to joining Qpex, Olga led efforts to discover novel beta-lactamase inhibitors and oversaw critical microbiology studies that supported the development and regulatory approval of VABOMERE™ (meropenem and vaborbactam) at Rempex Pharmaceuticals, Inc. She previously worked at Mpex Pharmaceuticals, where she oversaw key microbiology studies for QUINSAIR® (levofloxacin nebuliser solution) approval in cystic fibrosis, and at Microcide Pharmaceuticals, where she advanced the understanding of multidrug-resistant efflux pumps and the potential therapeutic use of inhibitors. Olga is an inventor with more than 20 patents or patent applications and has authored more than 50 original papers, article reviews and book chapters. In 2018, she was elected as a fellow of the American Academy of Microbiology.
Olga earned a Master of Science in molecular biology from Moscow State University in Moscow, Russia and a Doctor of Philosophy in molecular genetics from the Institute of Molecular Genetics at the Russian Academy of Sciences in Moscow. She completed post-doctoral research appointments at Massachusetts Institute of Technology in Cambridge, Massachusetts, California Institute of Technology in Pasadena, California, and Stanford University in Stanford, California.
